Study Stopped
Covid-19
Serratus Anterior Block and Catheter Use in Rib Fractures in the Emergency Department
SABRE
SABRE: Serratus Anterior Block and Catheter Use in Rib Fractures in the Emergency Department
1 other identifier
interventional
100
1 country
1
Brief Summary
The main aim of this study is to determine whether Serratus Anterior Plane (SAP) blockade provides improved pain relief after rib fractures compared to epidural administration of local anaesthetic. The investigators aim to show that SAP catheters (SAPC) can be placed in more situations and are less operator-dependent then thoracic epidural anaesthesia (TEA). This reduces the waiting time required to achieve satisfactory analgesia in the patient. Optimal analgesia allows early respiratory physiotherapy and reduction in the complications of multiple rib fractures. Pain from rib fractures is severe. The sensory nerves of the thoracic wall lie in the SAP and a single ultrasound-guided injection of local anaesthetic spreads widely and provides useful post-injury analgesia for several hours. If a catheter is left in the SAP, the nerve blockade can be maintained for several days. Rib Fracture pain is traditionally treated with oral/ intravenous analgesics or TEA. Opiate analgesia via patient controlled analgesia (PCA) can work very well but it is associated with excessive sedation, constipation, nausea and vomiting. Continuous TEA is generally regarded as the gold standard but it demands monitoring by adequately trained ward staff and is commonly associated with high failure rates and increased risk of complications. SAPC has also been used when TEA and PCA were not desirable. The primary outcome will be the amount of morphine analgesia required by the patient. Secondary outcomes will be pain scores (at rest and on movement), the side effects of morphine, complications of TEA/ SAPC, respiratory function changes and a quality of recovery assessment. The control group will have an epidural block and catheter placed. The treatment group will have SAP blocks and catheters placed under ultrasound guidance. Both blocks will be tested to ensure good pain relief. To avoid potential confounding effects, oral painkillers will adhere strictly to the study protocol.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Nov 2018
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 8, 2018
CompletedFirst Posted
Study publicly available on registry
October 18, 2018
CompletedStudy Start
First participant enrolled
November 5, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 30, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
November 30, 2025
CompletedOctober 14, 2022
October 1, 2022
7.1 years
October 8, 2018
October 12, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
intravenous morphine use via a patient controlled pump
This will be measured as the total amount (in milligrams) of intravenous morphine used via a patient controlled pump in 72 hours.
72 hours
Secondary Outcomes (4)
static and dynamic pain scores measurements
72 hours
side effects/ complications of interventions
72 hours
spirometry
72 hours
quality of recovery assessment
72 hours
Study Arms (2)
Serratus Anterior Plane Catheter
ACTIVE COMPARATORThoracic Epidural
PLACEBO COMPARATORInterventions
Insertion of a Serratus Anterior Plane Catheter to establish a continuous analgesic block with a local anaesthetic infusion
Insertion of a Thoracic Epidural Catheter to establish a continuous analgesic block with a local anaesthetic infusion
Eligibility Criteria
You may qualify if:
- Patients aged over 18 years suffering 2 or more rib fractures
You may not qualify if:
- Significant renal dysfunction (baseline creatinine \>150μmol/l - morphine contra- indicated)
- Pregnancy
- Patients with chronic pain on regular analgesic medication
- Patients with significant coagulation abnormality (unsafe to site blocks)
- Participation in another interventional study that will interact with this trial.
- Patients unable to give informed consent
- Hypersensitivity to local anaesthetic (or any other study drug).
- Contraindication to NSAID (peptic ulceration or sensitive asthma)
- Weight \<50kg
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Imperial College Healthcare NHS Trust
London, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- CARE PROVIDER
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 8, 2018
First Posted
October 18, 2018
Study Start
November 5, 2018
Primary Completion
November 30, 2025
Study Completion
November 30, 2025
Last Updated
October 14, 2022
Record last verified: 2022-10